Mattson Financial Services LLC cut its stake in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 1.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 21,751 shares of the medical equipment provider’s stock after selling 399 shares during the period. Mattson Financial Services LLC’s holdings in Boston Scientific were worth $2,336,000 as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in BSX. Brighton Jones LLC grew its holdings in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after purchasing an additional 226 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Boston Scientific by 17.2% in the first quarter. GAMMA Investing LLC now owns 25,554 shares of the medical equipment provider’s stock valued at $2,578,000 after purchasing an additional 3,745 shares in the last quarter. Dynamic Advisor Solutions LLC grew its holdings in shares of Boston Scientific by 8.1% in the first quarter. Dynamic Advisor Solutions LLC now owns 5,163 shares of the medical equipment provider’s stock valued at $521,000 after purchasing an additional 388 shares in the last quarter. Mission Wealth Management LP acquired a new position in shares of Boston Scientific in the first quarter valued at approximately $217,000. Finally, CENTRAL TRUST Co grew its holdings in shares of Boston Scientific by 108.7% in the first quarter. CENTRAL TRUST Co now owns 11,472 shares of the medical equipment provider’s stock valued at $1,157,000 after purchasing an additional 5,976 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.
Insider Activity at Boston Scientific
In other news, Director Edward J. Ludwig sold 4,000 shares of the company’s stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the transaction, the director owned 18,479 shares in the company, valued at approximately $1,959,328.37. This represents a 17.79% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $18,659,923.46. The trade was a 21.90% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 174,214 shares of company stock worth $17,972,457. Corporate insiders own 0.50% of the company’s stock.
Analyst Ratings Changes
Get Our Latest Analysis on BSX
Boston Scientific Trading Up 0.0%
Shares of Boston Scientific stock opened at $97.72 on Friday. The company has a fifty day simple moving average of $101.37 and a 200-day simple moving average of $101.75. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $109.50. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The stock has a market cap of $144.80 billion, a price-to-earnings ratio of 58.17, a PEG ratio of 2.35 and a beta of 0.61.
Boston Scientific (NYSE:BSX – Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter in the prior year, the business posted $0.62 EPS. The company’s revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.
Boston Scientific Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Featured Stories
- Five stocks we like better than Boston Scientific
- The Most Important Warren Buffett Stock for Investors: His Own
- Salesforce’s Long-Awaited Inflection is Here: Rally On!
- 10 Best Airline Stocks to Buy
- Rocket Lab USA Receives Wall Street Validation: Time to Buy?
- Insider Buying Explained: What Investors Need to Know
- Archer Buys Rival’s Patent Treasure Trove in Strategic Move
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.